First AD

Second AD

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in advanced endometrial cancer.

Next Steps With Pembrolizumab and Lenvatinib in Endometrial Cancer

Gynecologic Oncology

CLO-22-OSD1210 - /clinical/gynecologic-oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

TKI/Immunotherapy Combos in Endometrial Cancer

OncLive News Network®

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm. 

Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer

Prognosis and Survival Outcomes for Advanced/Recurrent Endometrial Cancer

Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer

Exploring Unmet Needs for the LEAP-001 Trial in Advanced Endometrial Cancer

Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer